Efficacy and Safety of Cycloset® Compared With Placebo When Added to Metformin

This study has been terminated.
(Failure to Recruit in a Timely manner)
Sponsor:
Information provided by (Responsible Party):
VeroScience
ClinicalTrials.gov Identifier:
NCT00441363
First received: February 27, 2007
Last updated: April 26, 2016
Last verified: April 2016

February 27, 2007
April 26, 2016
February 2005
February 2006   (final data collection date for primary outcome measure)
Change in Baseline to End of Study in HbA1c [ Time Frame: up to 24 weeks ] [ Designated as safety issue: No ]
Too few subjects were enrolled to assess outcome to pre-specified statistical power.
Change in Baseline to End of Study in HbA1c
Complete list of historical versions of study NCT00441363 on ClinicalTrials.gov Archive Site
  • Fasting Plasma Glucose and Lipids [ Time Frame: up to 24 weeks ] [ Designated as safety issue: No ]
  • Number of Serious Adverse Events Experienced by the Subjects [ Time Frame: up to 24 weeks ] [ Designated as safety issue: Yes ]
Fasting Plasma Glucose and Lipids
Not Provided
Not Provided
 
Efficacy and Safety of Cycloset® Compared With Placebo When Added to Metformin
A Randomized, Double-Blind, Parallel-Group Trial to Assess the Efficacy and Safety of Cycloset® Compared With Placebo When Added to Metformin in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to investigate the efficacy and safety of Cycloset® and placebo when added to metformin monotherapy (at least 1000 mg/day for 3 months prior to screening) in persons with type 2 diabetes mellitus who are not adequately controlled on metformin therapy alone.

In the previously conducted Phase III clinical trials, Cycloset® (up to a maximum dose of 4.8 mg/day), administered either as monotherapy or combined with sulfonylurea therapy, significantly reduced HbA1c, fasting and post-prandial glucose and fasting and post-prandial triglycerides in obese individuals with type 2 diabetes mellitus. Clinical studies that combined Cycloset® with metformin were not as part of the original Cycloset® clinical program because metformin was not commercially available in the United States at the time that the studies were initiated. The present study is designed to investigate the efficacy and safety of Cycloset® compared to placebo when added to metformin monotherapy in persons with type 2 diabetes mellitus who are not adequately controlled on metformin therapy alone.

A sufficient number of individuals will be screened to enroll up to 326 subjects;approximately 276 subjects are expected to complete treatment through study termination (Week 26). The study population will consist of individuals currently treated with metformin, for at least 3 months prior to the study start. Subjects who have ever received exogenous insulin therapy as part of an outpatient diabetes treatment regimen are to be excluded, as are those taking oral anti-diabetic agents other than metformin within 3 months of screening (e.g., sulfonylureas, thiazolidinediones,alpha-glucosidase inhibitors, or meglitinides). Subjects may be male or female(surgically sterile, postmenopausal, or using appropriate contraceptive methods if of childbearing potential), age 18 to 75 years, inclusive, and are to have a screening HbA1c value of ≥ 7.5% and <11.0% and a screening body mass index (BMI) in the range of 25 kg/m2 to 42 kg/m2, inclusive.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Type 2 Diabetes
Drug: Bromocriptine Mesylate
0.8 mg tablet
Other Name: Cycloset
  • Active Comparator: Bromocriptine Mesylate
    Bromocriptine mesylate 0.8 mg
    Intervention: Drug: Bromocriptine Mesylate
  • Placebo Comparator: Placebo
    Bromocriptine mesylate 0.8 mg matching placebo
    Intervention: Drug: Bromocriptine Mesylate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
66
March 2006
February 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Diagnosed with type 2 diabetes mellitus, for at least six months prior to screening.
  2. 18-75 years of age, inclusive.
  3. Male or if female, is either:

    • postmenopausal or
    • of childbearing potential and has used appropriate contraceptive methods
  4. Treated with a stable dose of metformin at least 3 months.
  5. Has not been treated with a sulfonylurea, thiazolidinedione, meglitinide, alpha-glucosidase inhibitor, or combination oral anti-diabetic therapy within 3 months prior to screening.
  6. Has not been on a regimen of lipid-lowering agents or if on such a regimen, it has been stable for a minimum of 6 weeks at screening.
  7. HbA1c value between ≥ 7.5% and < 11%, at screening (Visit 1) and Visit 3.
  8. Fasting plasma glucose measurement of ≤260 mg/dL at screening (Visit 1) and Visit 3.
  9. Fasting C-peptide value equal to or greater than the normal accepted minimum value (e.g. < 0.9 NG/ml).
  10. Stable body weight, i.e., not varying by > 10% for at least3 months prior to screening
  11. Body mass index (BMI) at screening of 25 kg/m2 to 42 kg/m2,inclusive.
  12. If treated for hypertension, the individual has been on stable therapy for 1 month prior to screening.

Exclusion Criteria:

  1. Prior exogenous insulin therapy as part of an outpatient diabetes treatment regimen.
  2. Type 1 diabetes mellitus
  3. Clinically significant history of cardiac disease or presence of cardiac disease, including MI, clinically significant arrhythmia, unstable angina pectoris, moderate to severe congestive heart failure, CABG, or angioplasty; or expected to require CABG or angioplasty during the study.
  4. Uncontrolled hypertension, defined as systolic blood pressure > 160 or diastolic blood pressure > 100 mmHg measured in sitting position at screening(Visit 1)

    Clinically significant history or presence of:

  5. Hepatic disease (i.e. impaired liver function, including having AST or ALT greater than three times the upper limit of normal)
  6. Renal disease (i.e. renal impairment with a serum creatinine ≥ 1.4 mg/dl)
  7. Central nervous system disease, including epilepsy
  8. CVA within the last 3 years.
  9. Less than 5 years remission from clinically significant malignancy.
  10. Major surgical operation within 3 months of screening.
  11. Organ transplantation.
  12. Evidence of acute or chronic illness including known or suspected HIV,HBV, or HCV infection.
  13. Currently abuses drugs or alcohol, including binge drinking, or history of abuse that in the investigator's opinion would cause the individual to be noncompliant.
  14. Regularly uses medications with addictive potential such as opiates,narcotics, tranquilizers, etc.
  15. Used drugs for weight loss, e.g., Xenical® (orlistat), Meridia® (sibutramine),Acutrim® (phenylpropanolamine), or similar over-the-counter medications within 3 months of screening.
  16. Known hypersensitivity to any components of the study drugs.
  17. Received any experimental drug or used an experimental device within 3 months of screening or will do so during the study.
  18. Has received unstable dose of fibric acid derivatives within 3 months of the screening.
  19. Requires regular use of systemic corticosteroids by oral, intravenous (IV),or intramuscular (IM) route, or regular use of potent, inhaled intranasal steroids that are known to have a high rate of systemic absorption.
  20. Prescription sympathomimetic drugs within 7 days of screening.
  21. Started therapy with an erectile dysfunction drug within 2 weeks prior to screening. The subject may not begin treatment with an erectile dysfunction drug during the study period; subjects previously taking erectile dysfunction drugs should do so only under medical supervision.
  22. Donated blood within 60 days of screening. Donation of blood also is prohibited during the study and for 30 days after completion of the study.
  23. Occupation that requires a rotation of shift work or working over night shifts.
Both
18 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00441363
165-AD-04-03-US-2
No
Not Provided
Not Provided
VeroScience
VeroScience
Not Provided
Study Director: Richard E Scranton, MD VeroScience
VeroScience
April 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP